Provectus Pharmaceuticals (OTCBB: PVCT) specializes in developing oncology and dermatology therapies. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. For further information, visit the Company’s Web site at www.pvct.com.

Noble Financial, a research driven, full-service investment banking boutique, is as discriminating with its invitations to institutional investors as it is with the companies invited to present. Rather than just focusing on crowding the conference floor, Noble Financial carefully invites a smaller audience of investors with a large appetite for the companies presenting; quality always trumps quantity. For more information or to view webcasts of today’s presentations, visit www.noblefcm.com.

Let us hear your thoughts below: